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Physiological Bases of Electric 
Stimulation as a New Approach  
to Glaucoma IOP Control
Luis Nino-de-Rivera, Diego Cervera and Paola Castillo-Juarez
Abstract
This Chapter focuses in the electrophysiological bases to support Trans Palpebral 
Electrical Stimulation TPES as a new alternative to control Intraocular Pressure IOP. 
Primary open Angle Glaucoma POAG is described in our approach as a dysfunction 
of the membrane potential of TM cells due to the dysfunction of the Maxi potas-
sium depended Calcium Channels BKCa2+ of the Trabecular Mesh TM. We review 
through the paper the main contributions about Trabecular mesh dysfunction 
related with Voltage dependent ionic channels. We also present in this paper new 
results in controlling intra ocular pressure IOP during one year of trans palpebral 
Electric stimulation in patients with Primary open-angle glaucoma (POAG).
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1. Introduction
Glaucoma is the first cause of blindness all over the world [1]. The main risk of 
this disease is an increase in intraocular pressure (IOP); this is due to the dysfunc-
tion of the trabecular mesh that does not let ocular drainage flux properly [2]. Most 
POAG treatments go to lower IOP decreasing the production of the aqueous humor 
(AH), however they do not go to the origin of the problem: the dysfunction of the 
trabecular mesh to control aqueous (AH) flux system [3–6]. We show in Figure 1 an 
approach of the IOP regulation mechanism, regulated by the flux that goes among 
TM cells. Cells have the capacity to grow or decrease their volumes adaptively, 
regulating the AH to go out. Consider the dysfunction of the conventional drainage 
of the TM cells if they lose the capacity to regulate their volume avoiding the right 
passage of intraocular flux among them. The Trabecular mash cells work like inside 
a tube, they let the aqueous humor pass amid the cells, then the AH goes from top 
to bottom passing trough the free spaces the cells liberate. The control of the AH 
flux is like balls in a tube varying their volume. The function of the TM cells is to 
regulate the passage of the humor through the free spaces depending on its volume. 
The highest cell volume, the lower flux to circulate among the balls, then higher 
pressure over inside the ocular globe surface. Ionic channels are device like swivels 
that allow to liberate pressure. Once the ionic channels fails closing abnormally, TM 
Cells do not control the AH passage among the “cell-ball”. Inside the ball there is a 
continuous production of water and K+ ions, if no liberation way of them, the cell 
grows in volume, increasing the pressure over the eye globe wall.
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The unfixed regulation on the opened-closed processes of depended voltage 
ionic channels (BKCa2+) affects the volume regulation of the cell. This inflamma-
tory process regulation is related with Voltage-dependent BKCa2+ channels VDCH 
which deregulation plays a central role in POAG illness [7–10]. BKCa2 ionic chan-
nels works like a hinge closing (holy or partially) to regulate the positive charge 
inside cell due to an increase of Ca + inside the TM cells. BKCa2+ works as a control 
system to regulate the positive charge ions inside the cell and then regulating the 
elasticity, contractility and then the volume of the cell. BKCa2+ regulates the posi-
tive charge inside the cell regulating the cell membrane potential.
2. Glaucoma and TM ion channel dysfunction
Stumpff and Soto [8, 9] reported that some tyrosine kinase in the trabecular 
mesh can capture the regulation function of the BKCa2+ channels, avoiding its vol-
ume regulation. Some Kinases avoids VDCH to act as a hinge regulating the volume 
of the cell capturing the Voltage sensor of the BKCa2+ sensor. The deregulation of 
the volume of the cell is, due to a dysfunction of some ionic channels is a typical 
channelopathy, it goes to an uncontrolled typical inflammatory process. TM cell 
dysfunction goes cell to its highest volume, losing the ability on going back  
them to a lower volume. This lost of flexibility shows: a) The incapacity of the 
BKCa+ channel to open and consequently to liberate H2O plus K+, as required.  
Figure 1. 
The scheme shows how aqueous humor AH, shown in the scheme like arrows, pass thought out TM cells. TM 
cells regulates the AH flux varying their volume in order to control the amount of AH flux.
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B) The deregulation of the membrane potential Vm,, is due to an excess of positive 
charge (+ch) inside the cytosol, not properly liberated by the BKCa+ channels, this 
is equivalent to keep closed the VDCH channel by keeping the membrane potential 
in the depolarization region avoiding the liberation of (+ch) and water. The right 
regulation of charges in the cell and its signaling (+ch) depends on the right Vm 
swing performance. A key point on this is how the Vm properly swings. We illustrate 
in Figure 2a the membrane potential Vm,. The depolarization region shows the 
+charge (+ch) growing inside the cell, this region goes from the equilibrium or rest 
voltage Vr to its highest positive value. The repolarization region occurs when the 
channel opens liberating K+. It goes from the highest Vm positive voltage (the high-
est positive charge allowed inside the cell), to the rest voltage Vr. This new approach 
to understand glaucoma let us to think in new solutions to force the cell membrane 
to get the right potential by an external voltage.
Moreover, Stumpff et al. showed [8] that tyrosine kinase inhibitors, like the 
Genestein with different dozes, reactivate the maxi-channels BKCa2+ sequestered 
by the tyrosine kinases. This relevant founding let understanding that repolarization 
Figure 2. 
We illustrate in Figure 2a the typical TM cell membrane potential Vm, and its depolarization, repolarization 
and hyperpolarization regions. We notice that the regulation of ions flux through the cells (K, Na, etc.) depends 
strongly on the right Vm levels. The dysfunction of the Vm potential keeping TM cells in the depolarization region, 
spouses high levels of water inside the cell due to lower KBCa currents, this increases TM cell volume avoiding 
the output of the AH flux through TM cells. Then this Vm potential dysfunction increases intraocular pressure. 
Figure 2b shows V-I relationship between glaucoma GTM and healthy TM cells. Figure 2c  shows the set of 
BKCa2+ ionic currents measured by Grant after the application of tyrosine kinase inhibitors
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and hyperpolarization region in TM cells play a central role in TM inflammatory 
dysfunction. We have concluded from this finding that relaxation of the trabecular 
meshwork is related with a dysfunction of the membrane voltage. Consequently, we 
can assure that POAG is a membrane potential Vm illness due to the dysfunction of 
BKCa2+ channels that affects the membrane potential Vm, keeping the cell mem-
brane at the repolarization region for long time avoiding relaxing the TM cells.
A relevant result showed by Stuff [8] was that the re-activation of BKCa2 chan-
nels resulted with the application of an agonist of tyrosine kinase, showing that 
ionic current of BKCa2 are rectifier channels type [8–10]. Stumpff results let us 
understand that inhibitors of tyrosine kinase recovers the ionic current flow trough 
the channel, and that as a consequence of that Vm goes a to normal status. We infer 
that the inverse is feasible too, recovering the BKCa+ open and close functionality 
by the right membrane potential. This is can be done from the application of an 
exogenous membrane Vm. voltage, if it is properly selected. This principle is widely 
used in Electrophysiology where patch clamp techniques apply a set DC voltage from 
positive to negative values to stimulate the cell membrane to measure the answer 
of the ionic currents in the cell varying the membrane voltage. Based on the above 
considerations we formulate the hypothesis that to recover the functionality of the 
BKCa+ maxi-channel can be achieved by a right exogenous membrane potential Vm. 
We proposed as our main working hypothesis that this can be achieved through an 
specific exogenous voltage applied to the tissue. A properly chosen exogenous volt-
age to the tissue will provide the right repolarization, depolarization and hyperpolar-
ization voltages over the membrane of the TM cells in order to recover its flexibility.
Another important result reported by Grant, et al., [10] shows that the V-I 
relationship between glaucoma GTM and healthy TM cells is clearly different in 
Electrophysiology analysis, as shown in Figure 2b. They study the performance of 
BKCa+ maxi-channel Ionic channels expressed in GTM and healthy TM cells, founding 
important differences among its current measured from a set of DC values. Reported 
results show important differences in the V-I relationship between GTM and TM 
for each specific ionic currents studied, consequently the performance regulation of 
normal TM is different from glaucoma GTM cells. Those differences founded in the 
electrophysiological properties of both groups let us to understand that POAG glaucoma 
illness is a dysfunction of the membrane potential of the GTM cells [9–12]. Figure 2c 
shows that for healthy TM cells BKCa+ is a rectifier current in the depolarization zone, 
however GTM shows a depressed BKCa+ current for positive DC voltages.
Daniel A. Ryskamp, et al. Published in 2016 an interesting paper about how 
TRPV4 regulates calcium homeostasis in mammalian eye. A. Ryskamp, et al. [12] 
shows that TRPV4 inhibition lowers IOP in GTM cells. They show too that an agonist 
of TRPV4 is a potential protector of the optic nerve. Due to TRPV4 are transient volt-
age dependent channels they could be manipulated, by exogenous voltages. TPES has 
demonstrated its beneficial effects in Retinosis Pigmentaria and IOP control proper-
ties [13–18], however new research is required to evaluate its protecting effects.
Figure 2b shows V-I relationship between glaucoma GTM and healthy TM cells. 
The voltage current V-I for healthy TM and GTM is clearly different. Healthy TM 
cells V-I curve shown in black squares is a typical rectifier function. However GTM 
in white squares vary its rest potential and decreases the V-I slope cells compared 
with healthy TM cells, this strongly modifies Vm. membrane potential in GTM cells. 
This Vm dysfunction keeps GTM cells in depolarization region, then avoiding the 
right control of the TM cells volume.
Figure 2c shows the set of BKCa2+ ionic currents measured by Grant after the 
application of tyrosine kinase inhibitors that goes back TM cells to normal Vm mem-
brane potential. Signals in Figure 2c fits more alike rectifier function depending on 
the tyrosine kinase inhibitors dosage.
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2.1 Micro stimulation procedure
The set of signals that fits more alike BKCa2+ after the application of tyrosine 
kinase inhibitors is shown in Figure 2c according with Stuff et al reports [8]. 
Consequently an exogenous voltage can be used as an adjuvant treatment to control 
IOP in patients with POAG. The waveform shown in Figure 2c fits more accurately 
with BKCa2+ ionic cells in TMC, however an enormous set of different signals 
conform the ionic currents environment in any cell. We show in Figure 3 a survey 
of the ionic currents that could be required to stimulate specific VDCH. A deeper 
understanding about the effects of TES in GTM cells is required to adjust the 
optimum parameters in TES, among others, waveform, frequency, amplitude and 
DC offset. TES requires special adjustment to fix the repolarization, depolarization 
and hyperpolarization zone for each target.
Our TES device reproduces electric profiles analogous to those reported by 
Stumpff [8, 9] in the BKCa2+ after the application of tyrosine kinase inhibitors, 
as well as many other ionic signals like Usui’s mode [11]. The flexibility to generate 
any desired action potential opens fresh opportunities to brand new experiments 
in TPES. Our stimulator system can reproduce any real biological ionic currents 
with 99.9% accuracy. These new approaches to stimulate TMCs open brand new 
opportunities to understand more precisely the neuro-regulation effects of electri-
cal stimulation in glaucoma and other degenerative illness.
2.2 Transpalpebral electrical microstimulation
TPES is not an invasive procedure as seen in Figure 4. This treatment modality 
is advantageous to conventional medical treatment consisting of hypotensive ocular 
drugs, which are associated with local and possible systemic side effects. This proce-
dure induces no changes on the ocular surface in opposition to ocular surface changes 
induced by the topical medication and the preservatives. No inflammatory phenom-
enon is generated; moreover, the immunological apparatus remains unaltered.
Figure 3. 
Our stimulator system can reproduce any ionic current from a mathematical model or from any real biological 
ionic currents with 99.9% accuracy. Typical calcium-activated chloride current (ICl(Ca)) and calcium-
activated potassium current (IK(Ca)) like Usui’s model [11], and as many others ionic currents must be 
available in dedicated TPES stimulators.
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Electrical micro stimulation focuses to the true cause of ocular hyperten-
sion, that is, the treatment of the dysfunctional trabeculum, while the rest of the 
therapy is focused on reducing the production of the aqueous humor or the exit 
of it through the unconventional route. In addition, it is important to emphasize 
the fact that this approach is highly cost efficient, when compared to anti-
glaucoma therapy. We report here, a one year follow-up clinical study with patients 
with POAG.
2.3 A non-conventional signal generator
A non-conventional TPES system to stimulate POAG patients requires the 
developed of friendly electronic systems with strict biomedical standards to 
assure no damage to the eye, keeping very low current inside the ocular glove 
and no temperature effects over the eyelid. It requires too a software interface 
that let call any one of pre programmed ionic currents. A graphical user interface 
allows in our system to choose among sixteen different stimulation signals. The 
Hardware-software based waveform generator can produce practically any sig-
nals, each one characterized by its shape, amplitude, and frequency. Waveform 
shape is acquired from a set of discrete X(n) waveforms previously defined, 
the reader can find important discussion about ionic currents parameters and 
waveforms in [19–22]. Waveforms can be acquired also graphically by a virtual 
draw tool or even by a mathematical model, Usui in [11] shows an interesting 
model to display waveforms from the retina complex network, however we 
require more research to find the optimum waveform parameters to apply in 
clinic. The selected TES stimulator signals are transmitted using a simple USB 
port connected to microcontroller that generates the stimulation signal required. 
The stimulation system designed in our group is able to recreate any complex 
waveform as the ones reported in electrophysiology cell. This scheme can be used 
to obtain a class of multichannel stimulator that can be the core part of several 
biomedical applications. The desired action potential is selected by a friendly 
software showed in Figure 5.
A set of sixteen predefined waveforms, as shown in Figure 3 let the physician 
select the signal and the parameters required, see Figure 5. The selected signal is 
programed into a microcontroller’s memory, allowing converting the digital data 
into an analogue output signal. Then the output of an electronic system can be con-
nected to the microelectrodes array to stimulate the cornea, as shown in Figure 4.
Figure 4. 
Shows the Transpalpebral electrical stimulation procedure on a POAG patient. TPES is applied over the eyelid 
by an electrode array and through an electronic system with control of wave-forms and its parameters, like: 
Amplitude, frequency, DC offset and stimulation time.
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3. Clinical founding
A year Follow-up of patients without surgical treatment (with and without 
topical treatment) is reported in this section. TPES is applied over the eyelid by an 
electrode array and through an electronic system with control of wave-forms and its 
parameters, like: amplitude, frequency, DC offset, stimulation time.
We report in this paper a one year TES study In 78 eyes from 46 patients (pilot 
group), 35 eyes of which 34.2% (n = 12) were specifically applied micro-stimulation 
and 65.8% (n = 23) applied micro-stimulation and topical treatment. The mean age was 
65.67 years (44–80 years), 66.6% (n = 12) were women and 33.3% (n = 6) men. The 
mean glaucoma diagnosis time for our sample was 82.06 months ±58.6 (Tables 1 and 2).
3.1 Results
During the follow-up of the patients, the IOP decrease was recorded for one 
year, baseline IOP = 18.45 mmHg ± 2.45, one month later IOP = 15.85 mmHg ± 3.03, 
3 months later IOP = 13.88 mmHg ± 1.90, after 6 months 14.65 mmHg ± 2.20 and 
Figure 5. 
Shows TPES interface system that let the physician to select the waveform among a set of sixteen pre defined Vm 
potentials to apply in TPES. The interface let define all parameters in TPES like: stimulation time, frequency, 
DC offset and voltage stimulation range.
Variable Man Women Total
Eyes (n) 12 23 35
Gender (%) 33.3 66.6 100
Mean Age ± DS (years) 68.33 ± 6.532 64.33 ± 9.717 65.8 ± 8.798
Rank (min,max) 63,80 44,77 44,80
Table 1. 
Demographic data of the patients in the pilot group, one year follow-up.
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Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.60000 1.78284 3.41716 < 0.001
3 4.57143 3.68859 5.45426 < 0.001
6 3.80000 2.82555 4.77445 < 0.001
12 3.80000 2.64317 4.95683 < 0.001
Table 2. 
Intraocular pressure reduction mean in the pilot group, after one-year follow-up.
Figure 6. 
Behavior of intraocular pressure in the one-year follow-up of the pilot group.
Figure 7. 
Box diagram of intraocular pressure behavior at one-year follow-up of the group of patients with GPAA.
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finally after one year IOP = 14.65 mmHg ± 3.09. Total decrease of 20.59% of the IOP 
after one year.
Total sample included 74 eyes of 40 patients, of which: 82.5% (n = 33) patients 
diagnosed with primary open-angle glaucoma, 2.5% (n = 1) with neovascular 
glaucoma, 2.5% (n = 1) with ocular hypertension and 12.5%  (n = 5) with congenital 
glaucoma. The average age was 59.03 years (12–81 years), 57.5% (n = 23) were 
women and 42.5% (n = 17) men. The mean glaucoma diagnosis time for our sample 
was 125.43 months ±159.52 (Figures 6–11).
Reduction of intraocular pressure in patients with GPAA, dividing the sample 
into 3 groups. From the previous sample, patients with GPAA were selected. 65 eyes 
of 34 patients were included. The mean age was 62.53 years (35–81 years), 58.82% 
Figure 8. 
Intraocular pressure behavior at one-year follow-up in the group of patients with GPAA, GN, GC and HTO.
Figure 9. 
Intraocular pressure behavior at one-year follow-up of group 1 [microstimulation only].
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(n = 20) were women and 41.17% (n = 14) men. The mean time of diagnosis of 
glaucoma for our sample was 88.94 months ±69,289 (Tables 3–5).
The sample was divided into 3 groups according to the treatment received. Group 
1 [microstimulation only] 17.64% (n = 6), group 2 [microstimulation + maximum 
tolerated drug treatment) 41.18% (n = 14), group 3 [microstimulation + pharmaco-
logical + surgical] 41.18% (n = 14). The average number of sessions per week was 1.71. 
In the total sample, the baseline IOP was 18.09 mmHg ± 3.97, 15.33 mmHg ± 3.37 a 
month, 13.86 mmHg ± 2.51 at 3 months, 14.21 mmHg ± 2.55, and 14.27 mmHg ± 2.91 
at 6 months. With a decrease in IOP per year of 21.11% (Table 6).
Group 1 [microstimulation only] the baseline IOP was 18.83 mmHg ± 1.64, at a 
month of 16.16 mmHg ± 2.85, at 3 months 13.83 mmHg ± 1.46, at 6 months 15.00 
mmHg ± 2.55 and at 13.41 mmHg ± 1.56. IOP decrease per year of 28.78% (Table 7).
Figure 11. 
Intraocular pressure behavior in one-year follow-up of group 2 [microstimulation + maximum tolerated 
pharmacological treatment + surgical treatment].
Figure 10. 
Intraocular pressure behavior at one-year follow-up of group 2 [microstimulation + maximum tolerated drug 
treatment].
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Group 1 [microstimulation only] the baseline IOP was 18.83 mmHg ± 1.64, at a 
month of 16.16 mmHg ± 2.85, at 3 months 13.83 mmHg ± 1.46, at 6 months 15.00 
mmHg ± 2.55 and at 13.41 mmHg ± 1.56. IOP decrease per year of 28.78% (Table 8).
Group 2 [microstimulation + maximum pharmacological treatment tolerated) 
the baseline IOP was 17.70 mmHg ± 2.64, a month of 14.81 mmHg ± 3.07, at 3 months 
13.29 mmHg ± 1.95, at 6 months 13.74 mmHg ± 1.99 and at 14.48 mmHg ± 3.50. With 
a decrease in IOP per year of 18.19%. It should be noted that 4 of the 14 patients were 
able to suspend 1 to 3 medications during the follow-up year.
Variable Man Women Total
Eyes (n) 31 43 74
Gender (%) 41.9 58.1 100
Mean Age ± DS (years) 57.59 ± 17.256 60.09 ± 15.687 59.03 ± 16.203
Rank (min,max) 12,80 17,81 12,81
Table 3. 
Demographic data of patients with GPAA, GN, GC and HTO.
Variable Man Women Total
Eyes (n) 27 38 65
Gender (%) 41.53 58.46 100
Mean Age ± DS (years) 60.64 ± 13.449 63.85 ± 11.018 62.53 ± 11.988
Rank (min,max) 36,80 35,81 35,81
Table 5. 
Demographic date of the group of patients with GPAA.
Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.72973 2.21911 3.24035 < 0.001
3 4.22973 3.58742 4.87204 < 0.001
6 3.91892 3.22044 4.61740 < 0.001
12 3.98649 3.20199 4.77098 < 0.001
Table 4. 
Mean intraocular pressure decrease in the one-year follow-up of the group with GPAA, GN, GC and HTO.
Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.75385 2.17932 3.32837 < 0.001
3 4.23077 3.53436 4.92718 < 0.001
6 3.87692 3.14329 4.61055 < 0.001
12 3.81538 2.98672 4.64405 < 0.001
Table 6. 
Average decrease in intraocular pressure in the one-year follow up of the group with GPAA.
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Group 3 [microstimulation + maximum tolerated pharmacological treatment + 
surgery] the baseline IOP was 18.15 mmHg ± 5.61, at a month of 15.50 mmHg ± 3.8, 
at 3 months 14.46 mmHg ± 3.24, at 6 months 14.34 mmHg ± 3.03 and per year 
14.46 mmHg ± 2.73. With a decrease in IOP per year of 20.33%. It should be noted 
that 3 of the 14 patients were able to suspend 1 to 2 medications during the year of 
follow-up (Table 9).
4. Conclusions, future and challenges
Transpalpebral Electrical Stimulation focuses to the true cause of ocular hyper-
tension, that is, the treatment of TM dysfunction, while the rest of the therapy is 
focused on reducing the production of the aqueous humor or the exit of it through 
the unconventional route [19, 20]. TPES is not only an alternative IOP therapy 
but also is a new way to face degenerative diseases, since the pathology is treated 
Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.65385 1.70527 3.60242 < 0.001
3 3.69231 2.39592 4.98869 < 0.001
6 3.80769 2.48514 5.13024 < 0.001
12 3.69231 2.23479 5.14983 < 0.001
Table 9. 
Mean decrease in intraocular pressure in the one-year follow-up of group 3 [microstimulation + maximum 
pharmacological treatment + surgical treatment].
Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.66667 .80274 4.53059 .009
3 5.00000 3.98630 6.01370 < 0.001
6 3.83333 1.77302 5.89365 .002
12 5.41667 4.04969 6.78364 < 0.001
Table 7. 
Average decrease in intraocular pressure in the one-year follow-up of group 1 [microstimulation only].
Follow-up (months) 95% confidence interval
Mean Inferior Superior Sig. (bilateral)
1 2.88889 2.07275 3.70503 < 0.001
3 4.40741 3.29792 5.51689 < 0.001
6 3.96296 2.93092 4.99500 < 0.001
12 3.22222 1.88147 4.56297 < 0.001
Table 8. 
Mean decrease in intraocular pressure in the one-year follow-up of group 2 [microstimulation + maximum 
pharmacological treatment].
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from another vision; the dysfunction of the voltage dependent channels looking its 
functionalization from an electronic medication. Electric medication is not new, 
however is not understood at all. The physiopathology bases discussed in this paper 
opens new alternatives to deal other degenerative illness where dysfunction of 
VDCH can be identified as the cause of the illness, some of them as an inflamma-
tory cell process.
TPES requires to study the effects of electrical stimulation in both: cells, tissues 
and complex structures like the eyeball. This new approach requires the develop-
ment of new flexible biomedical tools to stimulate the eyeball. A new future is 
coming with Biochips inside the eye to electrically stimulate the cornea. New 
challenges technology development requires TES in both: clinical applications and 
in cell culture to study the effects of electric stimulation of the trabecular mesh and 
some new alternatives to couple electrodes with both electronic systems and eye ball 
tissue. New challenges faces the need to measure inside the eyeball IOP integrated 
with biochips to stimulate the trabecular mesh to close the challenge to measure 
simultaneously IOP and control it by electric stimulation. New biochips with flex-
ible substrates like polyamide emerge as a new biocompatible material to be inte-
grated inside the eye to build complex systems to help people with glaucoma [23].
We propose a new medication procedure through the application of waveforms 
that can be generated from electronic technology feasible at hand. These new 
alternatives to treat degenerative ocular illness face new challenges and opportuni-
ties. However there is a long way to understand more precisely the neuro-protection 
effects of electrical stimulation at the trabecular mesh and at the inner retina. Most 
of diseases derivative in vision lost are related to Open Angle Glaucoma, Retinal 
degenerations (RDs), Retinitis pigmentosa (RP) and Age-related macular degen-
eration (AMD). It seems to be that most of them are related with a dysfunction of 
several voltage dependent ionic channels.
Optimal TPES parameters to target specific VDCH is still a challenge. New 
experiments are required to evaluate the effects of firing specific inner retinal 
neural structures. In our opinion, we show in this paper excellent results in control-
ling IOP during one year TPES stimulation as shown above. This pushes to look for 
new solutions to degenerative ocular illness.
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